NAC (N-Acetylcysteine)
NAC (N-Acetylcysteine) scored 8.0 / 10 (💪 Strong recommend) on the BioHarmony scale as a Substance → Amino Acid.
NAC (N-acetylcysteine) is the rate-limiting precursor to glutathione and the FDA-approved antidote for acetaminophen overdose, cutting hepatotoxicity to about 6 percent when given within 10 hours per Smilkstein 1988 (n=2,540). High-dose 600mg twice daily lowered COPD exacerbations 22 percent in the PANTHEON trial (Zheng 2014, n=1,006). It is cheap, oral, and well tolerated.
What is NAC (N-Acetylcysteine)?
NAC, short for N-acetylcysteine, is the acetylated form of the amino acid L-cysteine, and its main job is to hand your body the rate-limiting building block it needs to make glutathione, the master intracellular antioxidant. That single mechanism explains both its hospital reputation and its supplement appeal. As an antidote, NAC is FDA-approved for acetaminophen (paracetamol) overdose, where it replenishes the glutathione that the toxic metabolite burns through; Smilkstein et al. 1988 showed it cut serious liver injury to about 6 percent when given within 10 hours across 2,540 patients. It is also a decades-old mucolytic that thins airway mucus.
Beyond glutathione, NAC modulates glutamate through the cystine-glutamate antiporter, which is the basis for its emerging psychiatric uses in obsessive-compulsive disorder, hair-pulling, addiction relapse, and bipolar depression. NAC is distinct from glutathione itself (which it builds) and from GlyNAC (NAC plus glycine). It is cheap, oral, and has a benign safety record, which is why it scores well as a foundational compound rather than a hyped novelty.
Terminology
NAC sits at the intersection of emergency medicine, pulmonology, and psychiatry, so the jargon spans several fields. The terms below are the ones that change how you read the evidence: knowing that the overdose use is intravenous and acute, while the supplement use is oral and chronic, prevents you from expecting a hospital-grade effect from a daily capsule.
- NAC: N-acetylcysteine, the acetylated form of the amino acid L-cysteine.
- Glutathione: The body's main intracellular antioxidant, built from cysteine, glycine, and glutamate. NAC supplies the rate-limiting cysteine.
- Mucolytic: A substance that thins and loosens mucus, making it easier to clear from the airways.
- System xc-: The cystine-glutamate antiporter, the transporter NAC acts on to modulate glutamate in the brain.
- COPD: Chronic Obstructive Pulmonary Disease, a progressive lung condition where NAC reduces exacerbations.
- Y-BOCS: Yale-Brown Obsessive Compulsive Scale, the standard score used to measure OCD severity in trials.
- MADRS: Montgomery-Asberg Depression Rating Scale, used to measure depression severity.
- PCOS: Polycystic Ovary Syndrome, a hormonal disorder where NAC has been tested for ovulation induction.
- NAFLD: Non-Alcoholic Fatty Liver Disease.
- Anaphylactoid reaction: A non-allergic, histamine-mediated reaction that mimics anaphylaxis, seen mainly with rapid IV NAC.
- SMD: Standardized Mean Difference, a meta-analysis effect-size metric.
- NNT: Number Needed to Treat, how many patients must be treated for one to benefit.
How do you take NAC (N-Acetylcysteine)?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 3 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| oral | Capsule, tablet, effervescent, or sustained-release | 600 to 2,400 mg/day in divided doses | 600 to 3,000 mg/day |
| intravenous | IV infusion (Acetadote) | Weight-based 21-hour or modified 12-hour protocol for overdose | Hospital use only |
| inhaled | Nebulized solution (Mucomyst) | 3 to 5 mL of 10 to 20 percent solution, 2 to 4 times daily | Clinical use only |
Protocols
General antioxidant / glutathione support Mixed
- Dose
- 600 to 1,200 mg/day
- Frequency
- Once or twice daily
- Duration
- Ongoing
Common biohacker baseline. Stacks well with glycine for the GlyNAC combination (see /reports/glynac/).
COPD mucolytic (PANTHEON) Clinical
- Dose
- 600 mg
- Frequency
- Twice daily (1,200 mg/day)
- Duration
- 12 months in trial
The dose that reduced exacerbations; 600 mg once daily was null in BRONCUS.
Psychiatry adjunct (OCD, trichotillomania, addiction) Clinical
- Dose
- 1,200 to 2,400 mg/day
- Frequency
- Divided, twice daily
- Duration
- 8 to 12 weeks before judging response
Always adjunctive and clinician-supervised, not a standalone treatment.
How this score is calculated →
What are the benefits of NAC (N-Acetylcysteine)?
Upside contribution: 3.02
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 4.2 | 1.050 | |
| Breadth | 15% | 4.3 | 0.645 | |
| Evidence | 25% | 4.2 | 1.050 | |
| Speed | 10% | 3.8 | 0.380 | |
| Durability | 10% | 3.5 | 0.350 | |
| Bioindividuality | 15% | 3.6 | 0.540 | |
| Total | 4.015 |
Upside Rationale
The upside of NAC comes from a single elegant mechanism with an unusually wide reach: by refilling glutathione, it touches the liver, the lungs, the brain's glutamate system, and the reproductive axis. The strongest human evidence is its life-saving role in acetaminophen overdose, a setting where the effect is large, fast, and replicated across decades. The key boundary condition is that the dramatic wins happen in acute, high-dose, often intravenous medical settings, while the everyday oral supplement delivers quieter, slower benefits that a healthy person may barely feel.
Efficacy (4.2/5.0): The single strongest finding is overdose rescue: Smilkstein et al. 1988 (n=2,540) showed hepatotoxicity fell to 6.1 percent with NAC started within 10 hours, versus 26.4 percent at 10 to 24 hours, a near-curative effect that establishes high efficacy. The mucolytic effect is real and meaningful: Zheng et al. 2014 (n=1,006) cut COPD exacerbations from 1.49 to 1.16 per patient-year. In psychiatry, the magnitudes are clinically interesting where positive (52.6 percent OCD responders vs 15 percent in Afshar 2012), but inconsistent replication keeps efficacy below the top band.
Breadth of Benefits (4.3/5.0): NAC touches an unusually wide set of systems with at least one named endpoint each. Liver: overdose hepatoprotection plus ALT reduction in NAFLD per Khoshbaten 2010. Lungs: COPD exacerbation reduction. Brain and behavior: trichotillomania per Grant 2009, bipolar depression, and cannabis abstinence in adolescents. Reproductive: PCOS ovulation per Thakker 2015 and improved semen parameters in idiopathic male infertility. The boundary: contrast-induced nephropathy is a clear negative, so breadth is wide but not universal.
Evidence Quality (4.2/5.0): The evidence base is large and includes a Cochrane review: Poole 2019 pooled 38 trials and 10,377 patients for the mucolytic indication, and the overdose antidote rests on decades of replicated clinical practice plus landmark trials like Prescott 1979. NAC is non-patentable and cheap, which means much of its testing is investigator-led rather than industry-captured, a point in its favor. The honest deduction: psychiatric and renal claims show repeated non-replication (null results in the larger Berk bipolar trial, the adult Gray cannabis trial, and the PRESERVE 2018 contrast-nephropathy trial), which caps evidence below 4.5 despite the strong core.
Speed of Onset (3.8/5.0): Onset is bimodal. Intravenously for overdose, NAC works within minutes to hours, which is why the treat-early window in the overdose trials is decisive. For chronic oral use the timeline stretches to weeks for mucolytic and metabolic endpoints, and 8 to 12 weeks before judging a psychiatric response. Healthy users taking it as a daily antioxidant usually feel nothing acute, because the action is biochemical rather than stimulant-like.
Durability (3.5/5.0): Benefits are tied to continued dosing. The mucolytic and antioxidant effects depend on maintaining glutathione substrate, so they fade after stopping rather than persisting. There is no documented rebound or worsening on cessation, but neither is there a lasting structural change, so durability is moderate and chronic dosing is required for ongoing benefit.
Bioindividuality Upside (3.6/5.0): Responder profiles are real and somewhat predictable. The clearest strong responders are acetaminophen-overdose patients and people with chronic mucus-heavy COPD. In psychiatry, the most consistent signal appears in already-abstinent or adolescent substance users (Gray 2012, LaRowe 2013) rather than the general population. Weak responders include healthy adults seeking a felt antioxidant lift and anyone hoping to prevent contrast nephropathy, where the effect is absent.
What are the risks & downsides of NAC (N-Acetylcysteine)?
Downside contribution: 0.62 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 1.6 | 0.480 | |
| Side effects | 15% | 1.8 | 0.270 | |
| Cost | 5% | 1.3 | 0.065 | |
| Effort | 5% | 1.6 | 0.080 | |
| Opportunity | 5% | 1.8 | 0.090 | |
| Dependency | 15% | 1.2 | 0.180 | |
| Reversibility | 25% | 1.2 | 0.300 | |
| Total | 1.465 | |||
| Harm subtotal × 1.4 | 1.722 | |||
| Opportunity subtotal × 1.0 | 0.235 | |||
| Combined downside | 1.957 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.617 |
Downside Rationale
The downside of NAC is small and dominated by mild, reversible nuisances rather than real hazard. The most exposed groups are asthmatics using the inhaled mucolytic form, who can experience bronchospasm, and hospital patients receiving rapid IV infusions, who can have non-allergic anaphylactoid reactions. For the ordinary oral supplement user, the concern is essentially limited to GI tolerance and a sulfur smell. None of the serious effects are intrinsic to oral dosing; they are route-specific and clinical.
Safety Risk (1.6/5.0): Oral NAC is benign. Its decades of OTC and prescription use, plus a year-long COPD trial (Zheng 2014) with adverse events comparable to placebo, support a low safety-risk score. The rare serious event, a non-allergic anaphylactoid reaction, is route-specific to rapid IV infusion (Pakravan 2013) and is managed by pausing the infusion. Per the intrinsic-baseline rule, that hospital-route risk does not drive the oral supplement's safety. The only intrinsic caution is mild antiplatelet activity, relevant before surgery or with blood thinners.
Side Effect Profile (1.8/5.0): In RCTs the side effects are mild and infrequent: nausea, occasional diarrhea or loose stool, and a characteristic sulfur smell or taste that some find unpleasant. The inhaled form can provoke bronchospasm in reactive airways, which is why it is often paired with a bronchodilator. There is no neurological or systemic toxicity profile at supplement doses.
Financial Cost (1.3/5.0): NAC is one of the cheapest evidenced supplements available, typically $5 to $15 per month at 600 to 1,800 mg per day. There is little brand premium because the molecule is generic and non-patentable.
Time/Effort Burden (1.6/5.0): Administration is simple: one or two capsules daily, no cycling required, no special timing beyond a preference to take it away from large protein meals. The only minor effort is splitting higher psychiatric doses across the day.
Opportunity Cost (1.8/5.0): NAC rarely crowds out better options because it is cheap and additive, and it stacks cleanly with glycine as GlyNAC. The one caveat is that high-dose antioxidant timing around training can blunt exercise adaptation, so athletes may prefer to dose it away from key workouts. It does not compete with first-line treatments; in PCOS, metformin remains superior for ovulation.
Dependency/Withdrawal (1.2/5.0): There is no tolerance, dependence, or withdrawal syndrome. NAC is not psychoactive in a reinforcing way, and stopping it produces no rebound beyond the gradual return of the underlying baseline it was supporting.
Reversibility (1.2/5.0): Effects are fully reversible. Stopping NAC simply lets glutathione substrate availability return to baseline over days, with no lingering or permanent change. There is no taper requirement.
Is NAC (N-Acetylcysteine) worth it?
NAC is an 8.0 / 10 strong recommend: a cheap, broad, deeply-evidenced glutathione precursor with a genuinely life-saving core use and a benign safety record. The practical verdict is that almost anyone can take it safely, but the size of the benefit depends entirely on why you are taking it. It is essential and curative in acetaminophen overdose, reliably useful as a COPD mucolytic, and a reasonable clinician-supervised adjunct for OCD, hair-pulling, or addiction relapse. For a healthy person chasing a felt daily lift, it is a quiet biochemical support rather than something you notice. The strong tier is justified by the breadth, the safety, and the price, tempered by repeated non-replication in psychiatry and renal use.
✅ Best for: People who want one inexpensive, foundational antioxidant that doubles as respiratory and liver-detox support. Anyone with chronic mucus-heavy lungs or COPD, where the mucolytic benefit is Cochrane-backed. People exploring NAC as a clinician-supervised adjunct for OCD, trichotillomania, or substance-use relapse, especially adolescents or already-abstinent users where the signal is strongest. Women with PCOS-related subfertility using it alongside clomiphene. Biohackers who want the glutathione substrate that powers the GlyNAC longevity stack at a few cents a day.
❌ Avoid if: You have reactive airways or asthma and are considering the inhaled mucolytic form, which can trigger bronchospasm; the oral capsule is fine. You take anticoagulants or antiplatelets, or have surgery scheduled within two weeks, without clinician clearance, given NAC's mild antiplatelet activity. You are pregnant or lactating and using it outside medical guidance. You expect it to prevent contrast-induced kidney injury, which the large ACT and PRESERVE trials show it does not. You want a dramatic, same-day, stimulant-like effect from a subtle metabolic precursor.
What is NAC (N-Acetylcysteine) best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Liver / Detoxification: 8.0/10
Score: 8.0/10NAC earns 8.0/10 for liver and detoxification because its single most-proven use is hepatoprotection: as the FDA antidote for acetaminophen overdose it cuts hepatotoxicity to about 6.1 percent when started within 10 hours versus 26.4 percent at 10 to 24 hours per Smilkstein 1988 (n=2,540). The mechanism is direct glutathione repletion, the body's main detoxification antioxidant. For ongoing NAFLD support the data are thinner: Khoshbaten 2010 (n=30) showed ALT reductions versus vitamin C, but the trial is small and preliminary. The acute, life-saving liver use is the anchor; daily liver support is plausible but not yet strongly demonstrated.
Respiratory: 7.5/10
Score: 7.5/10Respiratory use scores 7.5/10 on real, Cochrane-backed mucolytic evidence. In the PANTHEON trial Zheng 2014 (n=1,006), 600 mg twice daily cut COPD exacerbations from 1.49 to 1.16 per patient-year (RR 0.78, 95% CI 0.67 to 0.90). A Cochrane review of 38 trials and 10,377 patients found mucolytics modestly increase exacerbation-free odds (Peto OR 1.73), with a number-needed-to-treat near 8. The benefit is dose-dependent: 600 mg once daily was null in BRONCUS Decramer 2005. It is not a fix for idiopathic pulmonary fibrosis, where monotherapy was null.
Antioxidant / Oxidative Stress: 7.5/10
Score: 7.5/10NAC is a 7.5/10 antioxidant because it is the rate-limiting precursor to glutathione, the body's master intracellular antioxidant, a mechanism characterized in detail by Bavarsad Shahripour 2014. It also acts as a direct sulfhydryl scavenger. The clinical proof of concept is overdose rescue, where rapid glutathione repletion prevents oxidative liver death. For healthy-person antioxidant optimization the felt benefit is subtle, and a moving surrogate marker is not the same as a clinical outcome, so the score reflects strong mechanism plus real rescue data rather than dramatic everyday effects.
Substance Use / Addiction Support: 6.5/10
Score: 6.5/10Addiction support scores 6.5/10 on a real but fragile glutamatergic signal. NAC modulates glutamate through the cystine-glutamate antiporter, which is plausibly anti-craving. Gray 2012 found cannabis-dependent adolescents on NAC had 2.4 times the odds of cannabis-negative urine tests (n=116), but the adult replication Gray 2017 (n=302) was null (OR 1.00). For cocaine, LaRowe 2013 helped only already-abstinent users delay relapse. The honest read: a relapse-prevention adjunct with the most consistent signal in already-abstinent or adolescent users, not a primary treatment.
Mood / Emotional Regulation: 6.0/10
Score: 6.0/10Mood scores 6.0/10 on the bipolar-depression adjunct literature, which is positive but unsettled. Berk 2008 (n=75) found a meaningful MADRS advantage (mean difference -8.05, 95% CI -13.16 to -2.95), and a meta-analysis Fernandes 2016 pooled five trials (n=574) to a small significant SMD of 0.37. But the larger Berk 2019 trial (n=181) found no between-group difference, undercutting the earlier signal. NAC is a reasonable clinician-supervised add-on for treatment-resistant mood, not a standalone antidepressant.
Fertility (Female): 6.0/10
Score: 6.0/10Female fertility scores 6.0/10 on PCOS ovulation-induction data. A meta-analysis of eight RCTs (n=910) by Thakker 2015 found NAC improved ovulation (pooled OR 3.13), pregnancy (OR 3.58), and live birth (OR 3.00) versus placebo. The catch: NAC was inferior to metformin head-to-head (ovulation OR 0.13). Badawy 2007 showed NAC added to clomiphene raised ovulation from 17.9 to 52.1 percent. A useful adjunct for PCOS-related subfertility, especially with clomiphene, but not first-line over metformin.
Anxiety: 5.5/10
Score: 5.5/10Anxiety and obsessive-compulsive symptoms score 5.5/10 on the OCD-adjunct data. Afshar 2012 (n=48) found NAC add-on improved Y-BOCS scores significantly (52.6 percent responders versus 15 percent on placebo) in treatment-refractory OCD over 12 weeks. The glutamatergic mechanism, modulating glutamate via the cystine-glutamate antiporter, is coherent for compulsivity and craving. The evidence base is small, single-site, and not consistently replicated in larger samples, so treat this as a low-risk, clinician-supervised adjunct to try when an SSRI alone is not enough, rather than a primary anxiety or OCD treatment. NAC is not a substitute for first-line therapy.
Immune Function: 5.0/10
Score: 5.0/10Immune function scores 5.0/10 on mechanism plus indirect signal. Glutathione status influences lymphocyte function and oxidative balance, and NAC has long been studied in respiratory and infectious contexts, with the mucolytic COPD benefit per Zheng 2014 (n=1,006, 22 percent fewer exacerbations) the most concrete real-world outcome. Direct immune-endpoint trials in otherwise healthy people are limited, heterogeneous, and often small, so the score reflects a plausible supportive role for someone with chronic respiratory or oxidative load rather than a demonstrated immune-boosting effect in the general population. It is supportive, not a stand-alone immune therapy.
| Use Case | Score | Summary |
|---|---|---|
| ○ Cognition / Focus | 4.5 | Mechanistic interest via glutathione and glutamate modulation, but no strong direct cognition RCT base in healthy adults. Neuroprotective framing is mostly preclinical. |
| ○ Neuroprotection | 4.5 | Glutathione repletion is plausibly neuroprotective and small Parkinson's and TBI signals exist, but human outcome trials are thin and the evidence stays mechanistic for now. |
| ○ Depression | 4.5 | Unipolar depression evidence is weaker than the bipolar-adjunct signal; the meta-analytic effect is small and pulled mainly by bipolar trials per Fernandes 2016. |
| ○ Metabolic Health | 4.0 | Indirect metabolic support through oxidative-stress reduction and homocysteine lowering, but no large metabolic-outcome RCT base. Not a glucose or weight intervention. |
| ○ Fertility (Male) | 4.0 | Ciftci 2009 (n=120) found 600 mg/day improved semen volume, motility, and viscosity over three months, but not concentration or morphology. A modest adjunct, not a proven fertility cure. |
| ○ Longevity / Lifespan | 4.0 | Longevity interest comes mostly from the glycine-plus-NAC (GlyNAC) glutathione-restoration work in older adults; standalone NAC has no human lifespan data. See /reports/glynac/ for the combination. |
| ○ Anti-Inflammatory | 4.0 | Glutathione repletion lowers oxidative and inflammatory load mechanistically, but dedicated anti-inflammatory clinical endpoints are inconsistent across trials. |
| ○ Hair / Nail Health | 4.0 | The trichotillomania (hair-pulling) data per Grant 2009 is about compulsive behavior, not hair growth; there is no evidence NAC improves hair or nail quality directly. |
| ○ Energy / Fatigue | 3.5 | Some users report a subtle lift tied to better oxidative balance, but NAC is not a stimulant and has no direct energy or fatigue RCT base in healthy people. |
| ○ Recovery / Repair | 3.5 | Antioxidant support could aid recovery, but high-dose antioxidant timing can blunt training adaptation, and there is no strong recovery-specific NAC RCT base. |
| ○ Stress / Resilience | 3.5 | Indirect via oxidative-load and glutamatergic pathways. No direct stress-resilience RCT base in healthy adults. |
| ○ Traumatic Brain Injury | 3.5 | A small military mild-TBI signal exists alongside the neuroprotective mechanism, but the human outcome base is thin and not replicated at scale. |
| ○ Kidney Function | 3.0 | Contrast-induced nephropathy prevention is the headline kidney claim, and it is settled negative: the large ACT (2011) and PRESERVE (2018) trials found NAC no better than placebo. Early small-trial enthusiasm did not replicate. |
| ○ Blood Sugar / Glycemic Control | 3.0 | Indirect via PCOS insulin-sensitivity context only. No meaningful direct glycemic-control RCT evidence in the general population. |
| ○ Heavy Metal / Toxin Burden | 3.0 | NAC binds some metals and supports glutathione-mediated clearance, but it is not a frontline chelator and dedicated human heavy-metal outcome trials are limited. |
| ○ Neuroplasticity | 3.0 | Glutamate modulation is mechanistically relevant, but human neuroplasticity endpoints are absent. Stays preclinical. |
| ○ Gut Health / Microbiome | 3.0 | Glutathione supports gut-barrier antioxidant defense mechanistically, but human gut-outcome trials for NAC are sparse. |
Frequently Asked Questions
What does NAC actually do in the body?
NAC supplies the rate-limiting cysteine your body needs to build glutathione, the master intracellular antioxidant, and also acts as a direct sulfhydryl scavenger. A third mechanism, modulating glutamate through the cystine-glutamate antiporter, underpins its psychiatric and addiction uses. The clearest proof of the glutathione mechanism is acetaminophen overdose rescue, where NAC replenishes the glutathione that the toxic metabolite depletes, as detailed by Bavarsad Shahripour 2014. In short, NAC is best understood as a glutathione precursor with a useful glutamate side effect.
How much NAC should I take and when?
Most general antioxidant and mucolytic use runs 600 to 1,800 mg per day, often split into two doses. The COPD mucolytic dose proven in the PANTHEON trial (Zheng 2014) is 600 mg twice daily, or 1,200 mg total; notably, 600 mg once daily was null in BRONCUS. Psychiatry trials for OCD, trichotillomania, and addiction commonly use 2,000 to 2,400 mg per day. Bioavailability is low at roughly 6 to 10 percent, so consistency matters more than perfect timing. Many people take it away from large protein meals.
What does the human evidence for NAC really show?
NAC is curative and FDA-approved for one thing, acetaminophen overdose, where Smilkstein 1988 (n=2,540) showed hepatotoxicity near 6 percent with early treatment. Its mucolytic COPD benefit is real and Cochrane-backed but modest and dose-dependent (Zheng 2014). Beyond that, the picture is honest but mixed: psychiatry results like trichotillomania (Grant 2009) and bipolar depression (Berk 2008) are positive but often fail to replicate in larger trials, and contrast-induced nephropathy prevention is settled negative (PRESERVE 2018). Strong where proven, promising but fragile elsewhere.
Is NAC safe to take long-term?
Oral NAC has a decades-long, benign safety record. The most common side effects are mild and reversible: nausea, occasional diarrhea, and a sulfur smell or taste. In the PANTHEON COPD trial adverse events on NAC were comparable to placebo over a full year. The rare serious reaction, a non-allergic anaphylactoid response, occurs almost exclusively with rapid intravenous infusion in the hospital, not with oral supplements (Pakravan 2013). There is no withdrawal syndrome and stopping is clean. Long-term oral use at standard doses is considered low risk.
Who should avoid NAC or be cautious with it?
Caution applies to a few groups. People with asthma should be careful with the inhaled mucolytic form, which can trigger bronchospasm; the oral supplement does not carry that risk. NAC may have mild antiplatelet activity, so anyone on blood thinners or facing surgery should clear it with a clinician. Pregnancy and lactation data are limited for supplement-dose use, so use only under medical guidance. Always treat psychiatric uses as clinician-supervised adjuncts, not self-directed primary treatment, given the fragile and sometimes non-replicating evidence.
NAC vs glutathione vs GlyNAC: which should I take?
NAC is the precursor that lets your body build its own glutathione, and it is cheaper and better studied than most direct glutathione supplements, whose oral absorption is debated (see /reports/glutathione/). GlyNAC combines NAC with glycine, the other amino acid in the glutathione molecule, and small studies in older adults suggest the pair restores glutathione and several aging markers better than NAC alone (see /reports/glynac/). For most people NAC is the simple, evidenced starting point; GlyNAC is the longevity-oriented upgrade if you want both substrates.
How fast does NAC work?
It depends entirely on the use. Intravenously for acetaminophen overdose, NAC works within minutes to hours, which is why early treatment is critical. For everyday goals, think in weeks to months: mucolytic and COPD benefits build over weeks of consistent dosing, and psychiatric trials for OCD, trichotillomania, and addiction typically run 8 to 12 weeks before judging response. Healthy people taking it as a general antioxidant often feel little acutely, because the wins are biochemical rather than stimulant-like. Patience and tracking beat expecting a same-day effect.
Why is NAC sometimes hard to buy as a supplement?
NAC sits in a regulatory gray zone. Because it was first approved decades ago as the drug Mucomyst, the FDA argued that NAC is excluded from the legal definition of a dietary supplement, and sent warning letters to sellers marketing it for hangovers. Some retailers briefly pulled it. The FDA later issued final guidance announcing enforcement discretion, meaning it will not object to lawfully formulated NAC supplements while it considers formal rulemaking. NAC remains widely available to buy in the US today.
What could change NAC (N-Acetylcysteine)'s score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The most plausible upgrade would come from a large, well-powered psychiatry replication confirming the OCD or addiction signal, which would lift Efficacy and Evidence together and could push NAC toward the low 9s. The most plausible downgrade would be further non-replication across its emerging uses, which would trim Evidence and Breadth. Safety is unlikely to move, since the oral profile is benign and well characterized over decades. The score is anchored by the overdose and mucolytic core, so the frontier indications are what move it.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| Large multi-site RCT confirms NAC for OCD or addiction | Efficacy 4.2 to 4.6, Evidence 4.2 to 4.6 | 8.7 / 10 💪 Strong recommend |
| GlyNAC-style trials show NAC drives durable healthspan markers | Breadth 4.3 to 4.6, Durability 3.5 to 3.9 | 8.5 / 10 💪 Strong recommend |
| Further psychiatric trials replicate the null results | Evidence 4.2 to 3.6, Breadth 4.3 to 3.9 | 7.4 / 10 💪 Strong recommend |
| A clean responder biomarker is identified for chronic use | Bioindividuality 3.6 to 4.2, Speed 3.8 to 4.1 | 8.4 / 10 💪 Strong recommend |
| New evidence shows high-dose antioxidant use blunts key adaptations | Opportunity 1.8 to 2.6 | 7.7 / 10 💪 Strong recommend |
| Regulatory reclassification restricts OTC supplement access | Effort 1.6 to 2.4, Cost 1.3 to 1.8 | 7.8 / 10 💪 Strong recommend |
Key Evidence Sources
- Smilkstein et al. 1988 - Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose, New England Journal of Medicine. n=2,540; hepatotoxicity 6.1% when NAC started within 10h vs 26.4% at 10-24h. The treat-early antidote evidence.
- Prescott et al. 1979 - Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning, British Medical Journal. n=100; near-complete protection when treated within 8 hours.
- Bateman et al. 2014 - Reduction of adverse effects from intravenous acetylcysteine (SNAP RCT), Lancet. n=222; modified 12h IV regimen cut vomiting and anaphylactoid reactions with equal efficacy.
- Zheng et al. 2014 - Twice-daily N-acetylcysteine 600mg for exacerbations of COPD (PANTHEON), Lancet Respiratory Medicine. n=1,006; exacerbations 1.16 vs 1.49 per patient-year, RR 0.78 (95% CI 0.67-0.90).
- Decramer et al. 2005 - Effects of N-acetylcysteine on outcomes in COPD (BRONCUS), Lancet. n=523, 600mg once daily; null for FEV1 decline and exacerbations. Dose-dependent benefit.
- Poole et al. 2019 - Mucolytic agents versus placebo for chronic bronchitis or COPD, Cochrane Database of Systematic Reviews. 38 trials, 10,377 patients; Peto OR 1.73 for staying exacerbation-free, NNT about 8.
- Martinez et al. 2014 - Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis, New England Journal of Medicine. NAC monotherapy null; FVC change at 60 weeks -0.18L vs -0.19L (p=0.77).
- Grant et al. 2009 - N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania, Archives of General Psychiatry. n=50; 56% much or very much improved vs 16% placebo (p=0.003). Landmark positive.
- Bloch et al. 2013 - N-acetylcysteine in the treatment of pediatric trichotillomania, Journal of the American Academy of Child and Adolescent Psychiatry. n=39; null (response 25% vs 21%). Contradicts the adult result.
- Afshar et al. 2012 - N-acetylcysteine add-on treatment in refractory OCD, Journal of Clinical Psychopharmacology. n=48; Y-BOCS improved (p=0.003); 52.6% responders vs 15% placebo. Small, single-site.
- Gray et al. 2012 - A double-blind RCT of N-acetylcysteine in cannabis-dependent adolescents, American Journal of Psychiatry. n=116; 2.4x odds of cannabis-negative urine (OR 2.4, 95% CI 1.1-5.2).
- Gray et al. 2017 - A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults, Drug and Alcohol Dependence. n=302; null (abstinence OR 1.00, 95% CI 0.63-1.59). Adult result did not replicate.
- LaRowe et al. 2013 - Is cocaine desire reduced by N-acetylcysteine?, American Journal on Addictions. n=111; benefit limited to already-abstinent subgroup (delayed relapse, lower craving).
- Berk et al. 2008 - N-acetylcysteine for depressive symptoms in bipolar disorder, Biological Psychiatry. n=75; MADRS mean difference -8.05 (95% CI -13.16 to -2.95, p=0.002).
- Berk et al. 2019 - The efficacy of adjunctive N-acetylcysteine in major depressive disorder and bipolar depression, BMC Medicine. n=181; null, no between-group difference at 16 weeks. Undercut the 2008 signal.
- Fernandes et al. 2016 - N-acetylcysteine in depressive symptoms and functionality: a meta-analysis, Journal of Clinical Psychiatry. 5 trials, n=574; pooled SMD 0.37 (95% CI 0.19-0.55, p less than 0.001).
- Thakker et al. 2015 - N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis, Obstetrics and Gynecology International. 8 RCTs, n=910; ovulation OR 3.13, pregnancy OR 3.58, live birth OR 3.00 vs placebo; inferior to metformin.
- Badawy et al. 2007 - N-acetylcysteine and clomiphene citrate for ovulation induction in PCOS, Acta Obstetricia et Gynecologica Scandinavica. Ovulation 17.9% (clomiphene) to 52.1% with added NAC; pregnancy 11.5%.
- Ciftci et al. 2009 - Effects of N-acetylcysteine on semen parameters in idiopathic male infertility, Urology. n=120, 600mg/day for 3 months; improved volume, motility, viscosity; no change in concentration or morphology.
- Khoshbaten et al. 2010 - N-acetylcysteine improves liver function in NAFLD, Hepatitis Monthly. n=30; significant ALT decrease vs vitamin C. Small, preliminary.
- ACT Investigators 2011 - Acetylcysteine for prevention of renal outcomes in patients undergoing angiography (ACT), Circulation. n=2,308; contrast-induced nephropathy identical 12.7% vs 12.7% (RR 1.00). Null.
- Weisbord et al. 2018 - Outcomes after angiography with sodium bicarbonate and acetylcysteine (PRESERVE), New England Journal of Medicine. n=4,993; composite 4.6% vs 4.5% (OR 1.02, p=0.88). Contrast-nephropathy question settled negative.
- Bavarsad Shahripour et al. 2014 - N-acetylcysteine in neurological disorders: mechanisms and therapeutic opportunities, Brain and Behavior. Mechanism review: cysteine donor for glutathione, direct antioxidant, glutamate modulation via system xc-.
- Dean, Giorlando and Berk 2011 - N-acetylcysteine in psychiatry: current therapeutic evidence and mechanisms, Journal of Psychiatry and Neuroscience. Synthesizes glutathione, glutamatergic, and neuroinflammatory pathways; 2,000-2,400 mg/day effective and well tolerated.
- Pakravan et al. 2013 - Risk factors and mechanisms of anaphylactoid reactions to acetylcysteine, British Journal of Clinical Pharmacology. Anaphylactoid reactions are non-IgE histamine-mediated and occur early in IV infusion, not with oral use.
What does the evidence say about NAC (N-Acetylcysteine)?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: High
Citations: Smilkstein 1988, Zheng 2014, Poole 2019, Grant 2009, Thakker 2015, Weisbord 2018
Traditional Medicine Systems
Confidence: Limited
Citations: Prescott 1979, Bavarsad 2014
Holistic Evidence for NAC (N-Acetylcysteine)
Six decades of hospital use and the modern trial record agree on the core: NAC is safe, reliably mucolytic, and life-saving in overdose, while its newer wellness and psychiatric claims remain the unsettled frontier.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- ALT During | Expected Down
- GGT During | Expected Down
- Homocysteine During | Expected Down
Pulse Dimensions to Watch
- Body During | Expected Watch | Primary
- Calm During | Expected Watch | Secondary
- Energy During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Mucus thickness / cough clearance Scale 1-5 | During | Expected Down
- Compulsive urge or craving intensity Scale 1-5 | During | Expected Down
- GI tolerance (nausea, loose stool) Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- New wheezing or chest tightness with the inhaled form (possible bronchospasm)
- Persistent vomiting or severe GI upset at higher oral doses
- Any rash, swelling, or breathing difficulty (rare anaphylactoid reaction, mainly IV)
Other interventions for Liver Detox
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 3.015 − 0.617 = 2.398
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (2.398 / 4.00) × 5 = 8.0 / 10
